Psoriatic Arthritis News

DESTIN, Fla. — Efficacy is just one of many factors that should be considered when choosing therapies for rheumatoid arthritis and psoriatic arthritis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Understanding which psoriatic arthritis disease domains are most important to the patient may help guide therapeutic decision-making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

DESTIN, Fla. — Making sense of the myriad targets for the myriad disease domains in rheumatoid arthritis and psoriatic arthritis presents ongoing challenges for every rheumatologist, a presenter said here..

The European Medicines Agency has recommended granting marketing authorization for bimekizumab for the treatment of adults with axial spondyloarthritis and active psoriatic arthritis, according to a UCB press release.

The emergence of new treatments and therapeutic approaches for psoriatic arthritis is improving physicians’ ability to treat a complicated, multifaceted disease.

Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.

Patients with psoriasis treated with interleukin-12/23 or IL-23 inhibitors may be less likely to progress to inflammatory arthritis than those treated with TNF inhibitors, according to data published in The Lancet Rheumatology.

The interleukin-17 inhibitor izokibep has demonstrated positive safety and efficacy data at 46 weeks among patients with psoriatic arthritis, according to a press release from its manufacturer.

Clinical data found “no evidence” of a higher short-term cancer risk, except for non-melanoma skin cancer, in patients with rheumatoid arthritis or psoriatic arthritis starting Janus kinase inhibitors vs. TNF inhibitors, researchers wrote.

Female patients with psoriatic arthritis who receive biologic disease-modifying antirheumatic drugs are more likely to have more severe disease and less likely to reach low or minimal disease activity vs. male patients, according to data.